Abstract:While it is now accepted that the gut microbiota contribute to the genotype-environment-lifestyle interactions triggering inflammatory bowel disease (IBD) episodes, efforts to identify the pathogen(s) that cause these diseases have met with limited success. The advent of culture-independent techniques for characterizing the structure and/or function of microbial communities (hereafter referred to as metagenomics) has provided new insights into the events associated with the onset, remission and recurrence of IBD. A large number of observational and/or case-control studies of IBD patients have confirmed substantive changes in gut bacterial profiles (dysbiosis) associated with disease. These types of studies have been augmented by new profiling approaches that support the identification of more ‘colitogenic' bacteria from numerically predominant taxa. Evidence of alterations in lesser abundant taxa such as the methanogenic archaea, to favor types that are more immunogenic, has also been forthcoming. Several recent longitudinal studies of patients with Crohn's disease have produced additional insights, including evidence for the role of ‘anti-inflammatory' microbiota in providing a protective effect and/or promoting remission. In summation, the implications of dysbiosis and restoration of a ‘healthy microbiota' in IBD patients requires definition beyond a taxonomic assessment of the changes in the gut microbiota during disease course. The available evidence does suggest that specific members of the gut microbiota can contribute either pro- or anti-inflammatory effects, and their ecological fitness in the large bowel affects the onset and recurrence of IBD. While metagenomics and related approaches offer the potential to provide novel and important insights into these microbiota and thereby the pathophysiology of IBD, we also need to better understand factors affecting the ecological fitness of these microbes, if new treatment of IBD patients are to be delivered.

The microbiota in inflammatory bowel disease

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Microbiota as key factors in inflammatory bowel disease

Gut microbiota in the pathogenesis of inflammatory bowel disease

Microbiota and IBD: Current knowledge and future perspectives

Gut microbiota and inflammatory bowel disease: The current status and perspectives

The microbiome in inflammatory bowel disease: current status and the future ahead

Gut Virome and Inflammatory Bowel Disease

The emerging role of the gut microbiota and its application in inflammatory bowel disease

Microbial genes and pathways in inflammatory bowel disease

Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases

Intestinal Microbes in Autoimmune and Inflammatory Disease

Gut Microbiota Resilience Mechanisms Against Pathogen Infection and its Role in Inflammatory Bowel Disease

The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy

Microbiota and its relationship with Inflammatory Bowel Diseases: An overview

Metabolic Host–Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD)

Environmental triggers in IBD: a review of progress and evidence

The human microbiome in disease and pathology

The gut microbiota and gut disease